Camille Samuels, TechCrunch Writer

Camille (Cami) Samuels is a partner at Venrock, focused on biotechnology, medical devices, and consumer health. Founded in 1969, Venrock is one of the world’s first venture capital firms, and she was its first partner. She currently serves on the boards of Iris, Mahzi, Ocelot, Unity (UBX), and XCaliber. She previously served on the boards of several of Venrock’s liquidated portfolio companies, including Corvidia (sold to Novo), RegenXBio (RGNX), and Spirox (now owned by Stryker). Prior to Venrock, Cami was a Managing Director at Versant Ventures, where she served on the board (or as a board observer) for several companies, including Genomic Health (GHDX), Jazz (JAZZ), Kythera (KYTH/sold to Allergan), Novacardia (sold to Merck), and ParAllele (sold to Affymetrix). Earlier in her career, Cami worked in corporate development at Genzyme, Millennium Predictive Medicine, and Tularik, and was a management consultant at LEK Consulting. Cami holds a BA in Biology from Duke University and an MBA from Harvard Business School (HBS), where she graduated as a Baker Scholar. She is a Henry Crown Fellow, serves on the Investment Advisory Committee at Mission Bay Capital, and serves on the HBS Global Advisory Board.